^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HER-2 exon 20 mutation

    i
    Other names: ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
    Entrez ID:
    2064
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations (PINNACLE) (NCT05378763)
    Phase 3
    Spectrum Pharmaceuticals, Inc
    Suspended
    Last update posted :
    02/15/2024
    Initiation :
    05/12/2022
    Primary completion :
    12/25/2027
    Completion :
    12/25/2028
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    docetaxel • Pozenveo (poziotinib)
    Her2-positive Lung Cancer Treated With Dedicated Drug (R2D2) (NCT03845270)
    Phase 2
    Intergroupe Francophone de Cancerologie Thoracique
    Completed
    Last update posted :
    12/19/2023
    Initiation :
    05/17/2019
    Primary completion :
    02/01/2021
    Completion :
    12/18/2023
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 insertion • HER-2 L755S • HER-2 exon 20 mutation • HER-2 YVMA • HER-2 exon 23 mutation
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab)
    A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer (NCT04311034)
    Phase 1/2
    RemeGen Co., Ltd.
    Completed
    Last update posted :
    12/18/2023
    Initiation :
    09/26/2018
    Primary completion :
    12/21/2021
    Completion :
    05/30/2022
    HER-2 • MET
    |
    EGFR mutation • HER-2 overexpression • HER-2 mutation • MET amplification • EGFR T790M • MET mutation • HER-2 exon 20 mutation
    |
    Aidixi (disitamab vedotin)
    A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation (NCT05745740)
    Phase 1/2
    RemeGen Co., Ltd.
    Not yet recruiting
    Last update posted :
    11/27/2023
    Initiation :
    04/01/2024
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    HER-2
    |
    HER-2 mutation • HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    Irene (pyrotinib) • Aidixi (disitamab vedotin)
    Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer (NCT06067776)
    Phase 1
    Jonathan Riess
    Not yet recruiting
    Last update posted :
    10/05/2023
    Initiation :
    01/01/2024
    Primary completion :
    01/01/2025
    Completion :
    11/01/2026
    HER-2 • BRAF • ALK • MET • RET
    |
    EGFR mutation • HER-2 overexpression • BRAF mutation • HER-2 amplification • EGFR L858R • HER-2 mutation • EGFR exon 19 deletion • MET amplification • EGFR T790M • RET fusion • HER-2 exon 20 insertion • ALK fusion • EGFR L861Q • RAS mutation • EGFR G719X • EGFR S768I • HER-2 exon 20 mutation • BRAF amplification • HER-2 exon 23 mutation
    |
    Erbitux (cetuximab) • Tagrisso (osimertinib) • Tukysa (tucatinib)
    Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) (NCT05332561)
    Phase 2
    German Cancer Research Center
    Recruiting
    Last update posted :
    07/06/2023
    Initiation :
    06/29/2023
    Primary completion :
    03/01/2030
    Completion :
    12/01/2030
    HER-2 • PD-L1 • PIK3CA • TMB • BRCA1 • BRCA2 • PARP1 • TACSTD2
    |
    HER-2 positive • BRCA2 mutation • BRCA1 mutation • TMB-H • HR positive • MSI-H/dMMR • HER-2 negative • PIK3CA mutation • HER-2 exon 20 insertion • PALB2 mutation • PD-L1 amplification • HR positive + HER-2 negative • HER-2 exon 20 mutation • UGT1A1*28 • UGT1A1*1*1 • HER-2 exon 23 mutation
    |
    Herceptin (trastuzumab) • Lynparza (olaparib) • Tecentriq (atezolizumab) • Perjeta (pertuzumab) • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC (NCT05800340)
    Phase 2
    Guangdong Provincial People's Hospital
    Recruiting
    Last update posted :
    04/05/2023
    Initiation :
    04/04/2023
    Primary completion :
    12/31/2024
    Completion :
    12/31/2026
    HER-2 • PD-L1 • BRAF • MET • RET
    |
    BRAF V600E • HER-2 amplification • HER-2 mutation • MET amplification • RET fusion • MET exon 14 mutation • MET mutation • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    carboplatin • Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • pemetrexed
    Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions (NCT04382300)
    Phase 2
    Shanghai Chest Hospital
    Recruiting
    Last update posted :
    01/28/2021
    Initiation :
    06/30/2020
    Primary completion :
    10/01/2022
    Completion :
    04/01/2023
    HER-2
    |
    HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation
    |
    Irene (pyrotinib) • thalidomide
    Responses to Chemotherapy of Patients With Non-small Cell Lung Cancer Harboring a Known Somatic Activating HER2 Mutation (NCT02827357)
    Phase N/A
    University Hospital, Toulouse
    Completed
    Last update posted :
    07/11/2016
    Initiation :
    03/01/2013
    Primary completion :
    09/01/2015
    Completion :
    09/01/2015
    HER-2
    |
    HER-2 exon 20 insertion • HER-2 exon 20 mutation • HER-2 exon 23 mutation